Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks

Trial Profile

Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs ORM 12741 (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms NEBULA
  • Sponsors Orion
  • Most Recent Events

    • 07 Feb 2018 Status changed from active, no longer recruiting to completed according to the Orion media release.
    • 13 Jan 2018 This trial has been completed in Bulgaria (End date: 2017-10-09), according to European Clinical Trials Database.
    • 19 Dec 2017 This trial was completed in Bulgaria (end date: 2017-10-09), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top